SS
DMAAR

Steve Schonfeld’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Steve Schonfeld’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-117,480
Closed -$22K – 2788
2025
Q4 		$22K Sell
117,480
-29,527
-20% -$5.73K ﹤0.01% 1924
2025
Q3 		$32K Sell
147,007
-267,485
-65% -$49.7K ﹤0.01% 2089
2025
Q2 		$49.8K Buy
414,492
+214,492
+107% +$27.6K ﹤0.01% 1884
2025
Q1 		$26K Buy
+200,000
New +$28.1K ﹤0.01% 2095

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Steve Schonfeld's DMAAR Position: Q1 2026 in Review

Steve Schonfeld sold out of Drugs Made In America Acquisition Corp Rights (DMAAR) in Q1 2026, closing a stake of 117,480 shares — an estimated $22K sold.

Steve Schonfeld first reported a position in DMAAR in Q1 2025 and held it in 4 quarters. The position peaked at $49.8K in Q2 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

  • Steve Schonfeld reported no remaining Drugs Made In America Acquisition Corp Rights position as of Q1 2026 after selling out during the quarter.
  • Steve Schonfeld sold 117,480 Drugs Made In America Acquisition Corp Rights shares in Q1 2026, an estimated $22K.
  • Steve Schonfeld first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and held it in 4 quarters.
  • Steve Schonfeld's Drugs Made In America Acquisition Corp Rights position peaked at $49.8K in Q2 2025.
  • 35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.